CTRI/2022/08/045009招募中3 期
Anti-Emetic Prophylaxis for Chemotherapy-Induced Vomiting Without Dexamethasone for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Open-Label, Multi-Center, Non-Inferiority, Phase III Randomized Controlled Trial. - CIVIC POD
Cancer Institute0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age between 4 to 18 years and diagnosed with cancer. Patients under four years have not been included as nausea assessment cannot be performed, dosing with olanzapine is not possible with the currently available tablet formulations, and data on olanzapine safety is unavailable.
- •2.Weight above 10 kg.
- •3.Receiving single-day or multi-day highly emetogenic chemotherapy (HEC) in a block.
- •4.Patients could have received prior chemotherapy. They need not be chemotherapy naïve.
- •5.Absence of vomiting 24 hours before enrollment.
- •6.Lansky play performance score of 60 or more for less than 16 years. Eastern Cooperative Oncology Group performance status of 0, 1, or 2 for 16-18 years.
- •7.Adequate organ function as confirmed by laboratory investigations within two weeks [Aspartate transaminase (AST) and Alanine transaminase (ALT) within four times upper limit of normal (ULN), serum bilirubin less than 2 mg/dL, serum creatinine within ULN].
- •8.Written informed consent from parents before enrollment. Children above 7-12 years of age will need to provide verbal assent. Children between 13 and 18 years of age must provide written assent.
排除标准
- •1.Patients receiving steroids as part of the chemotherapy regimen or steroids are needed as pre-medication to prevent allergic reactions.
- •2.Initiation of systemic corticosteroids within 72 hours before study drug administration.
- •3.Benzodiazepines or opioids are initiated 48 hours before treatment, except for single doses of triazolam, temazepam, or midazolam.
- •4.Use of antiemetics within 48 hours of treatment.
- •5.Patients with a primary brain tumor or brain metastasis.
- •6.Patients receiving concurrent radiotherapy with chemotherapy.
- •7.Patients in whom there are contraindications for corticosteroid use like uncontrolled diabetes mellitus, uncontrolled hypertension, active peptic ulcer disease and gastrointestinal bleeding.
- •8.History of allergy to any of the drugs used for anti-emetic prophylaxis.
- •9.Treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone for 30 days before or during the protocol therapy.
- •10.Receipt of mediation known to interact with olanzapine (e.g. fluoxetine, carbamazepine, omeprazole, rifampin)
- •11.A baseline ECG with clinically significant abnormalities, including QTc prolongation (more than or equal to 450 milliseconds)
- •12.Receipt of medication that may increase the potential for olanzapine toxicity.
- •13.Known cardiac arrhythmia, uncontrolled congestive heart failure, or acute myocardial infarction within the previous six months.
- •14.History of a neurological disorder including seizures and stroke within last six months.
- •15.Pregnant or breastfeeding patients.
研究者
相似试验
尚未招募
3 期
sing medicine Fosaprepitant along with other anti-vomiting medications for better control of vomiting and nausea in children receiving chemotherapyCTRI/2023/12/060941Cancer Institute (WIA)
Unknown
3 期
preventing chemotherapy induced nausea and vomiting in children without using steroid (dexamethasone)CTRI/2022/05/042750Cancer Institute
已完成
3 期
preventing chemotherapy induced nausea and vomiting without using steroid (dexamethasone)CTRI/2022/03/040906Cancer Institute350
尚未招募
不适用
Music therapy for chemotherapy induced nausea and vomitingCancerACTRN12622001495718Flinders Foundation24
招募中
Unknown
Hilotherapy for prevention of chemotherapy-induced peripheral polyneuropathy - A unicentric, prospective-controlled, randomized clinical trial for comparison of local hilotherapy vs. no therapy to prevent peripheral polyneuropathy during Taxan-based chemotherapy regimeG62.0C50.9C54C56C53Drug-induced polyneuropathyBreast, unspecifiedMalignant neoplasm of corpus uteriMalignant neoplasm of ovaryMalignant neoplasm of cervix uteriDRKS00027242niversitätsklinikum Ulm150